Fig. 6: In vivo efficacies of GQ1001 combined with HER2-targeting tyrosine kinase inhibitors (TKIs), and with chemotherapy and/or HER2-targeting monoclonal antibody in multiple primary or metastatic cancers.

Tumor growth curves (tumor sizes over time) showing in vivo anticancer efficacies of GQ1001 in combination with TKIs and other groups in patient-derived xenograft (PDX) mouse models: HER2-positive LD2-0017-201149 A single-dose GQ1001 with tucatinib, n = 6 per group; B single-dose GQ1001 with pyrotinib, n = 6 per group) and ST-02-0103 C single-dose GQ1001 with pyrotinib, n = 6 per group) gastric cancers: GQ1001 combined with tucatinib or pyrotinib showed supra-additively enhanced anticancer effects. In the LD2-0017-201149 model, endpoint analysis showed that tumor size was smaller in the T-DXd group compared with the GQ1001-tucatinib combination group on Day 35, before which there was a cross between the tumor growth line of the T-DXd group and that of the GQ1001-tucatinib combination group; GQ1001 combined with pyrotinib showed an anticancer efficacy similar to T-DXd. Excitingly, combination of GQ1001 with pyrotinib caused complete response (CR) in all animals of the LD2-0017-201149 model; BR050 (HER2 + ++) breast infiltrating ductal carcinoma (D single-dose GQ1001 with tucatinib, n = 5 per group; E 2-cycle GQ1001 (Q3W × 2 doses) with pyrotinib, n = 5 per group; F 2-cycle GQ1001 (Q3W × 2 doses) with neratinib, n = 5 per group): Single- or repeated-dose GQ1001 combined with tucatinib, pyrotinib, or neratinib also demonstrated supra-additive anticancer activity, similar to T-DXd. A, B were from the same experiment, and E, F from the same experiment; for better clarify, they are shown separately. Datapoints represent group mean, and error bars represent standard deviation. Statistical tests used and exact p-values are provided in Supplementary Tables 17–20, on the figures themselves, and/or in the Source Data file. Source data are provided as a Source Data file.